多烯磷脂酰胆碱联合二甲双胍和非诺贝特治疗NAFLD患者血清Pygo2和血脂水平变化*

doi:10.3969/j.issn.1672-5069.2020.04.019

摘要/Abstract

摘要： 目的探讨应用多烯磷脂酰胆碱联合二甲双胍和非诺贝特治疗非酒精性脂肪性肝病(NAFLD)患者血清人尾肢同源蛋白2(Pygo2)和血脂水平的变化。方法 2015年3月 ~2019年6月我院收治的NAFLD患者64例,被随机分为对照组32例和观察组32例。给予对照组二甲双胍片和非诺贝特胶囊口服治疗,观察组在此治疗的基础上加用多烯磷脂酰胆碱口服,两组均连续治疗12周。采用放射免疫分析法检测血清透明质酸(HA)和层黏蛋白(LN)水平,采用ELISA法检测血清Pygo2、高迁移率族蛋白B1(HMGB1)和白细胞介素-17(IL-17)。结果在治疗结束时,观察组血甘油三酯(TG)水平为(1.8±0.1)mmol/L,显著低于对照组【(2.7±0.4)mmol/L,P＜0.05】,总胆固醇(TC)水平为(4.6±0.4)mmol/L,显著低于对照组【(5.8±0.6)mmol/L,P＜0.05】,而血高密度脂蛋白胆固醇(HDL-C)水平为(1.9±0.5)mmol/L,显著高于对照组【(1.5±0.4)mmol/L,P＜0.05】;观察组血清丙氨酸氨基转移酶(ALT) 水平为(28.4±3.2)U/L,显著低于对照组【(35.9±4.1)U/L,P＜0.05】,天冬氨酸氨基转移酶(AST) 水平为(22.1±2.0)U/L,显著低于对照组【(32.6±3.4)U/L,P＜0.05】,血清HMGB1 水平为(13.7±1.5)μg/L,显著低于对照组【(20.2±2.4)μg/L,P＜0.05】,IL-17水平为(75.6±7.8)pg/mL,显著低于对照组【(90.7±10.2)pg/mL,P＜0.05】;观察组血清HA水平为(84.5±9.2)mg/L,显著低于对照组【(117.6±10.3)mg/L,P＜0.05】, LN水平为(91.2±10.2)μg/L,显著低于对照组【(108.7±11.3)μg/L,P＜0.05】,Pygo2水平为(37.5±4.1)μg/L,显著低于对照组【(42.4±5.0)μg/L,P＜0.05】。结论在运动和饮食控制的基础上,应用多烯磷脂酰胆碱联合二甲双胍和非诺贝特治疗可显著改善NAFLD患者脂代谢,抑制炎症反应和肝纤维化程度,短期临床疗效显著。

关键词: 非酒精性脂肪性肝病, 多烯磷脂酰胆碱, 二甲双胍, 非诺贝特, 人尾肢同源蛋白2, 治疗

Abstract: Objective The aim of this study was to investigate the s short-term efficacy of polyene phosphatidylcholine combined with metformin and fenofibrate in patients with nonalcoholic fatty liver disease (NAFLD). Methods 64 patients with NAFLD were recruited in our hospital between March 2015 and June 2019, and were randomly divided into control (n=32) and observation group (n=32). The patients in the control group were treated orally with metformin and fenofibrate capsules, while those in the observation group were additionally treated with polyene phosphatidylcholine capsules at the base of medicine mentioned above. The observation lasted for 12 weeks. Serum hyaluronic acid (HA), laminin (LN), high mobility group protein (HMGB1) and interleukin -17 (IL-17) were detected.Results At the end of 12 week observation, blood triglyceride (TG) level was (1.8±0.1)mmol/L, significantly lower than 【(2.7±0.4)mmol/L, P＜0.05】, total cholesterol (TC) level was (4.6±0.4)mmol/L, significantly lower than 【(5.8±0.6)mmol/L, P＜0.05】, while blood high density lipoprotein cholesterol (HDL-C) level was(1.9±0.5)mmol/L, significantly higher than 【(1.5±0.4)mmol/L, P＜0.05】 in the control; serum ALT level was (28.4±3.2)U/L, much lower than 【(35.9±4.1)U/L, P＜0.05】, AST level was (22.1±2.0)U/L, much lower than 【(32.6±3.4)U/L, P＜0.05】, serum HMGB1 level was (13.7±1.5)μg/L, significantly lower than 【(20.2±2.4)μg/L, P＜0.05】, and serum IL-17 level was (75.6±7.8)pg/mL, significantly lower than 【(90.7±10.2)pg/mL, P＜0.05】 in the control group; serum HA level was (84.5±9.2)mg/L, significantly lower than 【(117.6±10.3)mg/L, P＜0.05】, LN level was (91.2±10.2)μg/L, significantly lower than 【(108.7±11.3)μg/L, P＜0.05】, and serum Pygo2 level was (37.5±4.1)μg/L, much lower than 【(42.4±5.0)μg/L, P＜0.05】 in the control. Conclusion The administration of polyene phosphatidylcholine combined with metformin and fenofibrate tablets might obviously improve blood lipid metabolism and inhibit inflammatory reactions in patients with NAFLD, which needs long-term investigation.

Key words: Non-alcoholic fatty liver diseases, Polyene phosphatidylcholine, Metformin, Fenofibrate, Human tail limb homologous protein 2, Therapy

侯光华, 胡启江, 徐美华, 朱绍咏, 黄波. 多烯磷脂酰胆碱联合二甲双胍和非诺贝特治疗NAFLD患者血清Pygo2和血脂水平变化^*[J]. 实用肝脏病杂志, 2020, 23(4): 528-531.

Hou Guanghua, Hu Qijiang, Xu Meihua , et al. Short-term efficacy of polyene phosphatidylcholine combined with metformin and fenofibrate in patients with NAFLD[J]. Journal of Practical Hepatology, 2020, 23(4): 528-531.

参考文献

[1]Sporea I, Popescu A, Dumitrascu D, et al. Nonalcoholic fatty liver disease: status quo. J Gastrointestin Liver Dis, 2018, 27(4): 439-448.
[2]Neuschwander-Tetri B A. Non-alcoholic fatty liver disease. BMC Med, 2017, 15(1): 45-45.
[3]Shibuya T, Fushimi N, Kawai M, et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes Obes Metab, 2018, 20(2): 438-442.
[4]Huang, XL, Xu M, Chen Y, et al. Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly Chinese. Medicine,2015,94(40):1682.
[5]Kitade H, Chen G, Ni Y, et al. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients, 2017, 9(4): E387- E387.
[6]Runde J, Azzam RK. Hepatobiliary manifestations in systemic disease. Pediatr Ann, 2018,47(11):e458-e464.
[7]徐健. 恩替卡韦联合多烯磷脂酰胆碱治疗乙型肝炎肝硬化疗效初步研究. 实用肝脏病杂志, 2017, 20(5): 620-622.
[8]Perdomo CM, Fruhbeck G, Escalada J. Impact of nutritional changes on nonalcoholic fatty liver disease. Nutrients, 2019, 11(3): E677- E677.
[9]Samuel VT, Shulman G I. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab, 2018, 27(1): 22-41.
[10]Assuncao S, Sorte N, Alves CD, et al. Nonalcoholic fatty liver disease (NAFLD) pathophysiology in obese children and adolescents: update. Nutr Hosp, 2017, 34(3): 727-730.
[11]Guo J, Zhou Y, Cheng Y, et al. Metformin-induced changes of the coding transcriptome and non-coding rnas in the livers of non-alcoholic fatty liver disease mice. Cell Physiol Biochem, 2018, 45(4): 1487-1505.
[12]Cao YN, Baiyisaiti A, Wong CW, et al. Polyurethane nanoparticle-loaded fenofibrate exerts inhibitory effects on nonalcoholic fatty liver disease in mice. Mol Pharm, 2018, 15(10): 4550-4557.
[13]肖丽萍, 余新沛, 刘岗, 等. 多烯磷脂酰胆碱联合维生素E治疗非酒精性脂肪性肝炎合并2型糖尿病患者效果研究. 实用肝脏病杂志, 2016, 19(2): 172-175.
[14]Cao M, Li X, Zhang B, et al. The effect of polyene phosphatidyl choline intervention on nonalcoholic steatohepatitis and related mechanism. Am J Transl Res, 2016, 8(5): 2325-2330.
[15]刘扬河, 龙登毅, 贝筝, 等. 枯草杆菌二联活菌肠溶胶囊联合多烯磷脂酰胆碱治疗NAFLD疗效及对血清Pygo2、HMGB1和HIF-1α的影响. 实用肝脏病杂志, 2018, 21(4): 573-576.
[16]Chen Y, Ma Z, Zhong J, et al. Simultaneous quantification of serum monounsaturated and polyunsaturated phosphatidylcholines as potential biomarkers for diagnosing non-small cell lung cancer. Sci Rep, 2018, 8(1): 7137-7137.
[17]Cao Y, Xu L, Chen C, et al. Fenofibrate nanoliposome: Preparation and its inhibitory effects on nonalcoholic fatty liver disease in mice. Nanomedicine, 2016, 12(8): 2449-2458.
[18]Oscarsson J, Onnerhag K, Riserus U, et al. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: a double-blind, randomized, placebo-controlled study. J Clin Lipidol, 2018, 12(6): 1390-1403.
[19]周志菁, 黄永东. 多烯磷脂酰胆碱治疗中重度非酒精性脂肪性肝病患者疗效初步研究. 实用肝脏病杂志, 2018, 21(5): 733-736.
[20]Jiang Q, Liu W, Li X, et al. Detection of related substances in polyene phosphatidyl choline extracted from soybean and in its commercial capsule by comprehensive supercritical fluid chromatography with mass spectrometry compared with HPLC with evaporative light scattering detection. J Sep Sci, 2016, 39(2): 350-357.

多烯磷脂酰胆碱联合二甲双胍和非诺贝特治疗NAFLD患者血清Pygo2和血脂水平变化^*

Short-term efficacy of polyene phosphatidylcholine combined with metformin and fenofibrate in patients with NAFLD

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	胡亦懿, 翟英姬, 梅迪华, 张志侨, 罗晓亮, 黄燕峰, 杜国平. 余甘子提取物对非酒精性脂肪性肝病大鼠外周血Treg细胞及肝组织LXRα/FAS通路表达的影响^*[J]. 实用肝脏病杂志, 2020, 23(4): 488-491.
[2]	卓丽, 许敏, 邓浩辉. 阿舒瑞韦联合达拉他韦治疗慢性丙型肝炎患者初步疗效及其病毒准种变化和耐药变异特征分析^*[J]. 实用肝脏病杂志, 2020, 23(4): 504-507.
[3]	黄丽华, 杨正兵, 谭礼让. 熊去氧胆酸联合非诺贝特治疗PBC患者血清TGF-β、IFN-γ和IL-10水平变化^*[J]. 实用肝脏病杂志, 2020, 23(4): 520-523.
[4]	齐敬聪, 邢文静, 杜洋, 高辰玮. 熊去氧胆酸联合微生态制剂治疗原发性胆汁性胆管炎患者对肠道菌群的影响^*[J]. 实用肝脏病杂志, 2020, 23(4): 524-527.
[5]	周娜, 蒋磊, 吴冰冰. 阿托伐他汀治疗NAFLD患者对肝脂肪变和外周血Treg/Th17细胞的影响^*[J]. 实用肝脏病杂志, 2020, 23(4): 532-535.
[6]	陈曦, 陈照林, 董静, 宋海燕, 刘波, 张骏飞, 陈从新. 脐带间充质干细胞联合双重血浆分子吸附治疗慢加急性肝衰竭患者临床效果初步观察[J]. 实用肝脏病杂志, 2020, 23(4): 544-547.
[7]	张静, 周新民. 应用重组人血小板生成素减少肝硬化患者术前血小板输注疗效初步研究^*[J]. 实用肝脏病杂志, 2020, 23(4): 552-555.
[8]	陈照林, 董静, 宋海燕, 刘波, 张骏飞. 特利加压素联合腹水浓缩回输术治疗肝硬化并发顽固性腹水患者临床研究[J]. 实用肝脏病杂志, 2020, 23(4): 556-559.
[9]	全亚宁, 商晓杰, 孟璇, 高榆秀. 实时超声造影和融合影像导航下微波消融与手术治疗小肝癌患者疗效比较^*[J]. 实用肝脏病杂志, 2020, 23(4): 581-584.
[10]	郑雪, 宣之东, 王玉, 张丽静. 超声联合CT检查在肝恶性肿瘤射频消融治疗中的应用价值探讨^*[J]. 实用肝脏病杂志, 2020, 23(4): 589-592.
[11]	魏倩, 王艳, 游岚岚, 苟博. 超声引导下微波消融治疗早期泡型肝包虫病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2020, 23(4): 593-596.
[12]	吴鹏波,宋琪,俞媛洁,郭一天,饶倩,柴红,谭诗云. 姜黄素对非酒精性脂肪肝细胞模型保护作用以及机制研究[J]. 实用肝脏病杂志, 2020, 23(3): 324-327.
[13]	唐晓飞,钟梦菊,沈海娟. 柚皮素脂质体对非酒精性脂肪性肝病大鼠脂质代谢的影响及机制研究[J]. 实用肝脏病杂志, 2020, 23(3): 328-331.
[14]	唐新亚,侯森,焦营营. 卡托普利对非酒精性脂肪性肝病大鼠肝细胞脂肪变性的影响[J]. 实用肝脏病杂志, 2020, 23(3): 332-335.
[15]	艾国,王鸣,朱纪玲,邢铭友. 应用N-乙酰半胱氨酸治疗慢性乙型肝炎重度患者临床疗效初步研究[J]. 实用肝脏病杂志, 2020, 23(3): 336-339.